Differential effects of anticoagulants on the activation of platelets ex vivo

Circulation

Volumn 96, Issue 9, 1997, Pages 2877-2883

  Schneider, David J ^a,b   Tracy, Paula B ^a   Mann, Kenneth G ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Arteriosclerosis; Coagulation; Occlusion; Platelets

Indexed keywords

ENOXAPARIN; HEPARIN; HIRUDIN;

ADULT; ANTICOAGULANT THERAPY; ARTERIOSCLEROSIS; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0030664732     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.9.2877     Document Type: Article

References (39)

1. Davies MJ, Thomas AC. Plaque fissuring: cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
2. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Aral T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326:287-291.
3. Badimon L, Chesebro JH, Badimon JJ. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis of evolving thrombi. Circulation. 1992;86(suppl III):III-74-III-85.
4. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, Pelletier E, Juneau M, Stasiak J, DeGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
5. Coronary Thrombolysis in Perspective. In: Sobel BE, Collen D, eds. Principles Underlying Conjunctive and Adjunctive Therapy. New York, NY: Marcel Dekker; 1993.
6. Sobel BE. Clarifying the conundrum of conjunctive anticoagulation and coronary thrombolysis. Coron Artery Dis. 1995;6:83-86.
7. The Gusto Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
8. Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischaemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol. 1981;48:395-402.
9. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
10. Gray RP, Rendra TJ, Patterson DLH, Yudkin JS. Spontaneous platelet aggregation in whole blood in diabetic and non-diabetic survivors of acute myocardial infarction. Thromb Haemost. 1993;70: 932-936.
11. Becker RC, Tracey RP, Bovill EG, Mann KG, Ault K. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. Coron Artery Dis. 1994;5:339-345.
12. Trip MD, Cats VM, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
13. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84:613-617.
14. Lam JYT, Latour JG, Lesperance J, Waters D. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol. 1994;73:333-338.
15. Giles H, Smith REA, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994;24:69-72.
16. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous steptokinase in patients with acute myocardial infarction. Circulation. 1988;77:142-150.
17. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
18. Rand MD, Lock JB, Veer CV, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood. 1996;88: 3432-3445.
19. Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haemotol. 1994;88:364-371.
20. Swords NA, Mann KG. The assembly of the prothrombinase complex on adherent platelets. Arterioscler Thromb. 1993;13: 1602-1612.
21. Tracy PB, Eide LL, Bowie EJW, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59-63.
22. Leong L, Henriksen RA, Kermode JC, Rittenhouse SE, Tracy PB. The thrombin high-affinity binding site on platelets is a negative regulator of thrombin-induced platelet activation: structure-function studies using two mutant thrombins, quick I and quick II. Biochemistry. 1992;31:2567-2576.
23. Greco NJ, Tenner TE Jr, Tandon NN, Jamieson GA. PPACK-thrombin inhibits thrombin-induced aggregation and cytoplasmic acidification but does not inhibit platelet shape change. Blood. 1990;75:1983-1990.
24. Hawiger J, Parkinson S, Timmons S. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature (London). 1980;283:195-197.
25. McEver RP, Martin MN. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem. 1984; 259:9799-9804.
26. Dercksen MW, Weimar IS, Richel DJ, Breton-Gorius J, Vainchenker W, Slaper-Cortenbach ICM, Pinedo HM, Von Dem Borne AEGK, Gerritsen WR, Van Der Shoot CE. The value of flow cytometric analysis of platelet glycoprotein expression in CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. Blood. 1995;86:3771-3782.
27. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. J Biol Chem. 1994;37:23357-23366.
28. Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol. 1996;16: 1333-1339.
29. Merlini PA, Ardissino D, Oltrona L, Broccolino M, Coppola R, Mannucci PM. Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 1995;15:1675-1679.
30. Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettier DB, Rosenberg RD. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood. 1992; 79:2039-2047.
31. Dachary-Prigent J, Pasquet JM, Freyssinet JM, Nurden AT. Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+-ATPase inhibitors. Biochemistry. 1995;34:11625-11634.
32. Hirsh J, Raschk R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(suppl 4): 258S-275S.
33. Hirsh J, Levine M. Low molecular weight heparin. Blood. 1993; 79:1-17.
34. Legrand C, Morandi V, Mendelovitz S, Shaken H, Hartman JR, Panet A. Selective inhibition of platelet macroaggregate formation by a recombinant heparin-binding domain of human thrombospondin. Arterioscler Thromb. 1994;14:1784-1791.
35. Kelton JG, Smith JW, Warkentin TE, Hayward TE, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
36. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
37. Seiffert D, Schleef RR. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood. 1996;88:552-560.
38. Cohen M, Demers C, Gurfinkel E, Fromell G, Langer A, Turpie AGG, ESSENCE Group. Primary end point analysis from the ESSENCE trial: enoxaparin versus unfractionated heparin in unstable angina and non-Q-wave infarction. Circulation. 1996; 94(suppl I):I-554. Abstract.
39. Mirshahi M, Soria J, Neuhart E, Steg PG, Jacob P, Combe S, Soria C. Effect of heparin and enoxaparin on platelet interaction with fibrin clots. Thromb Res. 1992;65:187-191.